COVID-19

Dear Partners,

Necessitated by the unprecedented situation created by Covid-19, several industry events and tradeshows across the world have been postponed or stand cancelled. While we were looking forward to meet you, we at Piramal Pharma Solutions have had to take several precautionary measures to protect both our employees and customers, worldwide.

As we move forward in these extraordinary times, we want to assure you that that we are operational by taking the right safety measures and abundant precautions to ensure that we continue to support you and your patients.

While all of us are working remotely for now, you can schedule a discussion with us and we would be glad to help ensure you meet your pharmaceutical development and supply needs and thereby, your clinical and commercial timelines.

Please feel free to reach out to us at:
Stuart.Needleman@piramal.com

Our best wishes to colleagues, friends and family.

Best Regards,
Piramal Pharma Solutions

PiramalPharma Solutions Logo

Our Facility Expanding With The Market

steriline-lexington.jpg

According to recent trends in the market, the global contract pharmaceutical manufacturing industry is increasing at an average annual rate of 7.5% and is predicted to reach $79.24 billion in revenue by the year 2019. The market research firm, Visiongain, also expects a strong expansion in revenue for these companies to continue through 2025. Some key drivers in this growth include a growing demand for treatments based on highly potent active pharmaceutical ingredients (API) and regenerative medicines.

Keeping these figures in mind, and in order to meet the growing demands of our clients, Piramal Pharma Solutions-Lexington, Kentucky site has recently undergone a major $25 million expansion of its facilities. The expansion focuses on site capabilities and capacity for contract and commercial aseptic pharmaceutical manufacturing. Currently, the infrastructure of the manufacturing plant and warehouse have been redesigned including upgrades to equipment and utilities. The repurposing of the existing space will help the company expand its manufacturing services. This, in turn, will help improve operational efficiency and productivity.

The expansion has included new material airlocks to move products in and out of sterile environments and new process and prepping areas such as a new washroom. A new Microbiology laboratory space has been completed and construction is in progress for a new pass-through in the area. A new warehouse space has also been constructed and is currently in use. Other modifications have been made to the facilities in Phase 1 of the expansion project as well as the utilities. A new clean steam system and purified water skid have been installed to accommodate the increased need for these utilities.

The most exciting acquisition for the Lexington site is a new filling line. This line takes the now fragmented process of filling and completes it in one effective and efficient continuous process. This also allows the company to work with highly potent APIs in a safer way. Watch for a blog post coming soon on the new Steriline at Lexington.

With the growing demand for contract pharmaceutical manufacturing and the expansion into commercial manufacturing, this expansion benefits clients in several ways. The new microbiology laboratory provides more efficient coordination with the manufacturing operators. The new warehouse space provides optimal storage conditions for products and materials. Increasing capacity and movement of product with quicker fill times and less holdup of process times will provide clients with better service and an improved standard of care.

Great!